Cue Biopharma Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
CUE Nasdaq 8731 https://www.cuebiopharma.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Cue Biopharma Inc

2 “Strong Buy” Penny Stocks With Over 200% Upside on the Horizon - Mar 28th, 2023 2:45 pm
Cue Biopharma, Inc. (NASDAQ:CUE) Q4 2022 Earnings Call Transcript - Mar 24th, 2023 11:28 am
Q4 2022 Cue Biopharma Inc Earnings Call - Mar 22nd, 2023 11:37 am
Cue Biopharma Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Business Highlights - Mar 21st, 2023 8:10 pm
Cue Biopharma to Host Business Update Call and Webcast - Mar 15th, 2023 12:00 pm
Cue Biopharma to Present at Two March 2023 Investor Healthcare Conferences - Mar 1st, 2023 1:00 pm
Cue Biopharma Enters into a Strategic Collaboration and Option Agreement with Ono Pharmaceutical for CUE-401 - Feb 22nd, 2023 1:00 pm
Cue Biopharma’s Therapeutic Immuno-STAT Biologics to be Featured in Oxford University Presentation at the 67th Biophysical Society Annual Meeting - Feb 16th, 2023 3:30 pm
Cue Biopharma Announces the Appointment of Dr. Rafi Ahmed to its Scientific Advisory Board - Feb 16th, 2023 1:00 pm
Investors in Cue Biopharma (NASDAQ:CUE) have unfortunately lost 81% over the last three years - Feb 14th, 2023 10:49 am
Cue Biopharma to Present at Two February 2023 Scientific Conferences - Feb 1st, 2023 1:00 pm
Cue Biopharma Announces Chief Medical Officer Transition - Jan 23rd, 2023 1:00 pm
Cue Biopharma to Present at Two Upcoming Investor Healthcare Conferences - Nov 22nd, 2022 1:00 pm
Public Ventures LLC Completes First Public Company Financing as a Broker-Dealer for Cue Biopharma, Inc. (Nasdaq:CUE) - Nov 17th, 2022 2:00 pm
Cue Biopharma Third Quarter 2022 Earnings: EPS Beats Expectations, Revenues Lag - Nov 16th, 2022 10:33 am
Cue Biopharma Reports Third Quarter 2022 Financial Results - Nov 14th, 2022 9:01 pm
Cue Biopharma Announces $30 Million Private Investment in Public Equity (PIPE) Financing - Nov 14th, 2022 1:20 pm
Cue Biopharma Presents New Positive Data from Ongoing Phase 1 Trial of CUE-101 in Combination with KEYTRUDA(R) for Recurrent/Metastatic HPV+ Head and Neck Cancer at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting - Nov 10th, 2022 2:00 pm
Cue Biopharma to Present at Two Upcoming Investor Healthcare Conferences in November - Nov 9th, 2022 1:00 pm
Cue Biopharma, Inc. (NASDAQ:CUE) drops to US$91m and insiders who purchased earlier this year lose another US$33k - Oct 17th, 2022 4:18 pm